EISAI CO

🇯🇵Japan

Country: 🇯🇵Japan

Ownership: Public

Established: 1941-12-06

Employees: 11K

Market Cap: $12B

Website: http://www.eisai.co.jp

Clinical Trials

A Phase 1 Comparative Study of E2022 Current and New Patch Formulations

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: E2022- Current Formula Tape
Drug: E2022 Matching Placebo- Current Formula Tape
Drug: E2022- New Formula Tape
Drug: E2022 Matching Placebo- New Formula Tape

First Posted Date: 2014-01-23

Last Posted Date: 2014-02-21

Lead Sponsor: Eisai Co., Ltd.

Target Recruit Count: 34

Registration Number: NCT02042729

A Multiple Dose Pharmacokinetic Study of Perampanel in Korean Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Perampanel

First Posted Date: 2013-12-25

Last Posted Date: 2015-03-03

Lead Sponsor: Eisai Co., Ltd.

Target Recruit Count: 20

Registration Number: NCT02020486

Locations: 🇰🇷
Inje University Busan Paik Hospital, Busan, Korea, Republic of

Investigation of the Safety and Efficacy of Iguratimod in Patients With Rheumatoid Arthritis

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Iguratimod

First Posted Date: 2013-05-10

Last Posted Date: 2018-11-05

Lead Sponsor: Eisai Co., Ltd.

Target Recruit Count: 2747

Registration Number: NCT01850966

A Phase 1 Study of E2022 Tape Formulation for Different Application Sites and Intervals in Japanese Healthy Elderly Males

Phase 1

Completed

Conditions: Healthy Elderly Male

Interventions: Drug: E2022 Tape Formulation

First Posted Date: 2013-04-30

Last Posted Date: 2023-06-18

Lead Sponsor: Eisai Co., Ltd.

Target Recruit Count: 48

Registration Number: NCT01843556

A Single-dose Study in Healthy Japanese Male Adults to Evaluate Pharmacokinetics and Pharmacodynamics of E5501 5 mg Tablet (Study E5501-J081-015)

Phase 1

Completed

Conditions: Healthy

First Posted Date: 2013-01-24

Last Posted Date: 2014-02-03

Lead Sponsor: Eisai Co., Ltd.

Target Recruit Count: 15

Registration Number: NCT01774773

A Phase 1 Study of MORAb-004 in Patients With Solid Tumor (Study: MORAb-004-J081-103)

Phase 1

Completed

Conditions: Solid Tumor

Interventions: Drug: MORAb-004

First Posted Date: 2013-01-23

Last Posted Date: 2016-11-10

Lead Sponsor: Eisai Co., Ltd.

Target Recruit Count: 46

Registration Number: NCT01773434

A Phase 1 Single Dose Study of E6011 in Japanese Healthy Adult Male Subjects (Study E6011-J081-001)

Phase 1

Completed

Conditions: Healthy Male Volunteers

Interventions: Drug: E6011
Drug: E6011 Matching Placebo

First Posted Date: 2012-11-21

Last Posted Date: 2014-02-14

Lead Sponsor: Eisai Co., Ltd.

Target Recruit Count: 64

Registration Number: NCT01731275

A Study of E7080 in Subjects With Advanced Thyroid Cancer

Phase 2

Completed

Conditions: Thyroid Cancer

Interventions: Drug: E7080 capsule

First Posted Date: 2012-11-20

Last Posted Date: 2020-08-14

Lead Sponsor: Eisai Co., Ltd.

Target Recruit Count: 51

Registration Number: NCT01728623

Pharmacological Effect of Lysozyme for Chronic Obstructive Pulmonary Disease and Asthma With Sputum Symptom

Phase 4

Completed

Conditions: Asthma
Chronic Obstructive Pulmonary Disease

Interventions: Drug: Placebo
Drug: lysozyme 90 mg

First Posted Date: 2012-10-29

Last Posted Date: 2014-07-18

Lead Sponsor: Eisai Co., Ltd.

Target Recruit Count: 48

Registration Number: NCT01715493

A Multicenter, Open-label Study for E7040 in Japanese Subjects With Hypervascular Tumor and Subjects With Arteriovenous Malformation

Phase 3

Completed

Conditions: Hypervascular Tumor and Arteriovenous Malformation

Interventions: Device: E7040

First Posted Date: 2012-09-03

Last Posted Date: 2016-02-22

Lead Sponsor: Eisai Co., Ltd.

Target Recruit Count: 28

Registration Number: NCT01677624

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy